[ad_1]
This “Disease Analysis: Seasonal Flu Vaccine” Report has been added to ResearchAndMarkets.com provide.
Influenza is an acute respiratory disease caused by influenza viruses belonging to the Orthomyxoviridae family. The Orthomyxoviridae family is a group of enveloped viruses with segmented, negative-sense, single-stranded RNA genomes. Two influenza viruses dominate humans, type A and type B, which spread between late autumn and early spring every year, causing seasonal epidemics.
The virus is spread from person to person by inhaling tiny droplets of aerosol virus secreted by coughing, sneezing, or talking with an infected person. The virus can also survive on hard surfaces for approximately 24-48 hours, and can be infected by touching a contaminated surface and then touching the nose or mouth. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that influenza causes 90 to 450,000 illnesses each year and 12,000 to 61,000 deaths each year.
The latest key points
-
The seasonal influenza vaccine market in the United States, Japan, and five major European markets (France, Germany, Italy, Spain, and the United Kingdom) is expected to continue to expand in the next 10 years, mainly due to pricing vaccines for the subgroup of premium senior citizens, including quadrivalent Forms of Fluzone High-Dose (HD) and Fluad, and…
The full story on Benzinga.com
[ad_2]
Source link
